NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Proniras Corporation

Proniras Corporation

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://proniras.com/

Last Round

Series B

Feb 1, 2024

Total Funding Raised

$21.25M

Company Overview

Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2G

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

biotechnologysmall-molecule therapeuticsdrug developmentCNS disordersopioid withdrawaltezampanelbiotech startupclinical trialsglutamate receptor antagonistseizure disorderscentral nervous systemdrug discoverygovernment grantspharma R&Dnon-dilutive funding

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Proniras Corporation Comparables

Compare Proniras Corporation with similar companies based on industry and business-model similarity.

Proniras Corporation comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aether Therapeutics
80%
Kinoxis Therapeutics
77%
BioCorRx Inc
73%

Proniras Corporation Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 1, 2024
GrantSep 17, 2020
Series AJul 12, 2019
AcceleratorApr 27, 2018

Key People

Founding team and executive leadership

Christopher Toombs

Cofounder and Chief Scientifc Officer

Founding Team

Proniras Corporation Investors

Notable investors and investment history

Proniras Corporation investors
InvestorRounds
Accelerator Life Science PartnersSeries B, Accelerator
ARCH Venture PartnersAccelerator, Series B
WRF CapitalSeries B, Accelerator
Public Health Emergency Medical Countermeasures EnterpriseAccelerator
ARCH Venture PartnersAccelerator, Series B
Washington Research Foundation CapitalSeries B, Accelerator
Alexandria Venture InvestmentsAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 17, 2020

    $12M grant awarded by the National Institute on Drug Abuse.

Proniras Corporation Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Proniras Corporation Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Proniras Corporation's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range3
Year Founded2017
Last FundingFeb 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.